全文获取类型
收费全文 | 11275篇 |
免费 | 433篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 137篇 |
儿科学 | 171篇 |
妇产科学 | 88篇 |
基础医学 | 1304篇 |
口腔科学 | 185篇 |
临床医学 | 657篇 |
内科学 | 2534篇 |
皮肤病学 | 220篇 |
神经病学 | 1233篇 |
特种医学 | 667篇 |
外科学 | 1487篇 |
综合类 | 31篇 |
预防医学 | 342篇 |
眼科学 | 400篇 |
药学 | 817篇 |
中国医学 | 17篇 |
肿瘤学 | 1469篇 |
出版年
2023年 | 50篇 |
2022年 | 97篇 |
2021年 | 160篇 |
2020年 | 68篇 |
2019年 | 112篇 |
2018年 | 186篇 |
2017年 | 147篇 |
2016年 | 202篇 |
2015年 | 187篇 |
2014年 | 267篇 |
2013年 | 356篇 |
2012年 | 542篇 |
2011年 | 604篇 |
2010年 | 351篇 |
2009年 | 313篇 |
2008年 | 621篇 |
2007年 | 702篇 |
2006年 | 737篇 |
2005年 | 732篇 |
2004年 | 761篇 |
2003年 | 667篇 |
2002年 | 726篇 |
2001年 | 238篇 |
2000年 | 205篇 |
1999年 | 222篇 |
1998年 | 186篇 |
1997年 | 192篇 |
1996年 | 156篇 |
1995年 | 144篇 |
1994年 | 133篇 |
1993年 | 124篇 |
1992年 | 147篇 |
1991年 | 142篇 |
1990年 | 111篇 |
1989年 | 111篇 |
1988年 | 113篇 |
1987年 | 85篇 |
1986年 | 106篇 |
1985年 | 102篇 |
1984年 | 90篇 |
1983年 | 79篇 |
1982年 | 55篇 |
1981年 | 43篇 |
1980年 | 38篇 |
1979年 | 47篇 |
1978年 | 31篇 |
1977年 | 39篇 |
1976年 | 26篇 |
1973年 | 22篇 |
1969年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
111.
Shinji Ohmori Yasuo Ohno Tadashi Makino Toshio Kashihara 《European journal of pharmaceutics and biopharmaceutics》2005,59(2):289-297
The purpose of this study was to apply an electronic nose system for evaluation of unpleasant odor in tablets containing L-cysteine, an unpleasant odor drug, and demonstrate the odor masking ability of thin-layer sugarless coated tablets, which we have newly developed, by both electronic nose system and sensory evaluations. We demonstrated the qualitative evaluation of the unpleasant odor using air as a reference indicator and the quantitative evaluation of the unpleasant odor using the distances between air and samples in the electronic nose system evaluation. The electronic nose system evaluation was positively and well-correlated with the sensory evaluation by volunteers. We suggest that the electronic nose system evaluation is appropriate as an alternative or a support method for sensory evaluation by volunteers. As the results of both electronic nose system and sensory evaluations, we demonstrated that the thin-layer sugarless coated tablets have excellent masking ability of the unpleasant odor, equivalent to that of sugar-coated tablets due to the dense coating layers. 相似文献
112.
Li F Sone S Maruyama Y Takashima S Yang ZG Hasegawa M Honda T Yamanda T Kubo K 《European radiology》2000,10(11):1782-1791
Computed tomography scans, including thin-section high-resolution computed tomography (HRCT), occasionally fail to differentiate
between small non-cancerous nodules from lung cancers. We describe nine such lesions ( < 20 mm in diameter) initially identified
through our screening program for lung cancer using CT scanning. Pathological diagnoses included nodular fibrosis (n = 4), granuloma (n = 1), cryptococcoma (n = 1), localised organising pneumonia (n = 1), inflammatory pseudo-tumour (n = 1) and sclerosing haemangioma (n = 1). High-resolution CT findings, together with MRI findings with contrast-enhanced dynamic studies, were retrospectively
evaluated. Additional cases should be identified and radiologically characterised in order to reduce the number of non-cancerous
tumours that are treated by unnecessary surgery.
Received: 28 February 2000; Accepted: 29 February 2000 相似文献
113.
Asahi H Takeda M Takashima M Koshida K Uchibayashi T Namiki M Minato H Siba N Hasegawa M 《Hinyokika kiyo. Acta urologica Japonica》2000,46(6):397-400
We report a case of chromophobe cell renal carcinoma. A 27-year-old male suffered from right flank pain and gross hematuria. Drip infusion pyelography and ultrasonographic examination revealed a right renal mass and it was diagnosed as renal oncocytoma by needle biopsy of the right kidney. He was referred to our hospital for the operation and right radical nephrectomy was performed. The cut surface of the tumor was beige in color. The cytoplasm of the tumor cells stained positively for colloidal iron and showed a negative reaction for Vimentin. From these results, this tumor was given a diagnosis of chromophobe cell renal carcinoma. 相似文献
114.
Takuji Suzuki Tatsuro Fukuhara Masashi Tanaka Akira Nakamura Kenichi Akiyama Tomohiro Sakakibara Daizo Koinuma Toshiaki Kikuchi Ryushi Tazawa Makoto Maemondo Koichi Hagiwara Yasuo Saijo Toshihiro Nukiwa 《Clinical cancer research》2005,11(1):58-66
Cancer immunotherapy by fusion of antigen-presenting cells and tumor cells has been shown to induce potent antitumor immunity. In this study, we characterized syngeneic and allogeneic, murine macrophage/dendritic cell (DC)-cancer fusion cells for the antitumor effects. The results showed the superiority of allogeneic cells as fusion partners in both types of antigen-presenting cells in an in vivo immunotherapy model. A potent induction of tumor-specific CTLs was observed in these immunized conditions. In addition, the immunization with DC-cancer fusion cells was better than that with macrophage-cancer fusion cells. Both syngeneic and allogeneic DC-cancer fusion cells induced higher levels of IFN-gamma production than macrophage-cancer fusion cells. Interestingly, allogeneic DC-cancer fusion cells were superior in that they efficiently induced Th1-type cytokines but not the Th2-type cytokines interleukin (IL)-10 and IL-4, whereas syngeneic DC-cancer fusion cells were powerful inducers of both Th1 and Th2 cytokines. These results suggest that allogeneic DCs are suitable as fusion cells in cancer immunotherapy. To further enhance the antitumor immunity in the clinical setting, we prepared DCs fused with IL-12 gene-transferred cancer cells and thus generated IL-12-secreting DC-cancer fusion cells. Immunization with these gene-modified DC-cancer fusion cells was able to elicit a markedly enhanced antitumor effect in the in vivo therapeutic model. This novel IL-12-producing fusion cell vaccine might be one promising intervention for future cancer immunotherapy. 相似文献
115.
116.
Yuri Takahashi Yasuo Miyoshi Chie Takahata Natsumi Irahara Tetsuya Taguchi Yasuhiro Tamaki Shinzaburo Noguchi 《Clinical cancer research》2005,11(4):1380-1385
PURPOSE: LATS1 and LATS2 are tumor suppressor genes implicated in the regulation of cell cycle. Methylation status of the promoter regions of these genes as well as its correlation with their mRNA levels were studied in human breast cancers. Correlation of LATS1 and LATS2 mRNA levels with clinicopathologic characteristics of breast tumors were also studied. EXPERIMENTAL DESIGN: Methylation status of promoter regions of LATS1 and LATS2 was studied by a methylation-specific PCR and mRNA expression levels of LATS1 and LATS2 were determined by a real-time PCR assay in 30 breast cancers. In addition, correlation of LATS1 and LATS2 mRNA levels with clinicopathologic characteristics was studied in 117 breast cancers. RESULTS: Methylation-specific PCR showed that of 30 tumors, LATS1 promoter region was hypermethylated in 17 tumors (56.7%) and LATS2 promoter region was hypermethylated in 15 (50.0%) tumors. LATS1 mRNA levels in breast tumors with hypermethylation (2.15 +/- 0.37, mean +/- SE) were significantly (P < 0.01) lower than those without hypermethylation (6.09 +/- 1.38), and LATS2 mRNA levels in breast tumors with hypermethylation (1.42 +/- 0.66) were also significantly (P < 0.01) lower than those without hypermethylation (3.10 +/- 1.00). The decreased expression of LATS1 or LATS2 mRNA was significantly associated with a large tumor size, high lymph node metastasis, and estrogen receptor and progesterone receptor negativity. Furthermore, the decreased expression of LATS1 mRNA, but not LATS2 mRNA, was significantly (P < 0.05) associated with a poor prognosis. CONCLUSIONS: Hypermethylation of the promoter regions of LATS1 and LATS2 likely plays an important role in the down-regulation of their mRNA levels in breast cancers, and breast cancers with a decreased expression of LATS1 or LATS2 mRNA levels have a biologically aggressive phenotype. 相似文献
117.
Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. 总被引:5,自引:0,他引:5
Tomonori Nakazato Keisuke Ito Yasuo Ikeda Masahiro Kizaki 《Clinical cancer research》2005,11(16):6040-6049
PURPOSE: Green tea polyphenol, (-)-epigallocatechin-3-gallate, has been shown to inhibit cellular proliferation and induce apoptosis of various cancer cells. The aim of this study was to investigate the possibility of (-)-epigallocatechin-3-gallate as a novel therapeutic agent for the patients with B-cell malignancies including multiple myeloma. EXPERIMENTAL DESIGN: We investigated the effects of (-)-epigallocatechin-3-gallate on the induction of apoptosis in HS-sultan as well as myeloma cells in vitro and further examined the molecular mechanisms of (-)-epigallocatechin-3-gallate-induced apoptosis. RESULTS: (-)-Epigallocatechin-3-gallate rapidly induced apoptotic cell death in various malignant B-cell lines in a dose- and time-dependent manner. (-)-Epigallocatechin-3-gallate-induced apoptosis was in association with the loss of mitochondrial transmembrane potentials (Deltapsim); the release of cytochrome c, Smac/DIABLO, and AIF from mitochondria into the cytosol; and the activation of caspase-3 and caspase-9. Elevation of intracellular reactive oxygen species (ROS) production was also shown during (-)-epigallocatechin-3-gallate-induced apoptosis of HS-sultan and RPMI8226 cells as well as fresh myeloma cells. Antioxidant, catalase, and Mn superoxide dismutase significantly reduced ROS production and (-)-epigallocatechin-3-gallate-induced apoptosis, suggesting that ROS plays a key role in (-)-epigallocatechin-3-gallate-induced apoptosis in B cells. Furthermore, a combination with arsenic trioxide (As2O3) and (-)-epigallocatechin-3-gallate significantly enhanced induction of apoptosis compared with As2O3 alone via decreased intracellular reduced glutathione levels and increased production of ROS. CONCLUSIONS: (-)-Epigallocatechin-3-gallate has potential as a novel therapeutic agent for patients with B-cell malignancies including multiple myeloma via induction of apoptosis mediated by modification of the redox system. In addition, (-)-epigallocatechin-3-gallate enhanced As2O3-induced apoptosis in human multiple myeloma cells. 相似文献
118.
Yumiko Kasugai Hiroyuki Tagawa Yoshihiro Kameoka Yasuo Morishima Shigeo Nakamura Masao Seto 《Clinical cancer research》2005,11(23):8265-8272
PURPOSE: Increases in gene dosage through DNA amplification represents a common feature of many tumors and can result in the up-regulation of tumor-promoting genes. Our recent genome-wide, array-based comparative genomic hybridization analysis of 66 cases of diffuse large B-cell lymphoma found that genomic gain of 6p21 was observed in as many as 17 cases, including 14 cases with low-level copy number gain and three cases with high-level copy number gains (amplifications). EXPERIMENTAL DESIGN AND RESULTS: To identify the target gene(s) for 6p21 amplification, we constructed a detailed amplicon map at the region of genomic amplification with the aid of high-resolution contig array-based comparative genomic hybridization glass slides, consisting of contiguously ordered bacterial artificial chromosome/P1-derived artificial chromosome clones covering 3 Mb throughout the 6p21 amplification region. Alignment of the amplifications identified a minimally overlapping 800 kb segment containing 15 genes. Quantitative expression analysis of the genes from both patient samples and the SUDHL9 cell line revealed that CCND3 and BYSL (1.9 kb telomeric to the CCND3 gene locus) are the targets of 6p21 genomic gain/amplification. CONCLUSIONS: Although it is known that t(6;14)(p21;q32) induces aberrant overexpression of CCND3 in B-cell malignancies, we were able to show that CCND3, which encodes the cyclin D family member protein that controls the G1-S phase of cell cycle regulation, can also be a target of genomic gain/amplification. Overexpression of CCND3 through genomic amplification is likely to lead to aberrant cell cycle control, although the precise biological role of BYSL with respect to tumorigenesis remains to be determined. 相似文献
119.
Takahiro Zenda MD Takaharu Masunaga Bungo Fuwa Toshihide Okada Yasuo Ontachi Yukio Kondo Shinji Nakao Hiroshi Minato 《Journal of gastrointestinal cancer》2005,36(2):113-119
A 49-yr-old Japanese woman underwent upper gastrointestinal endoscopy because of nonspecific dyspepsia. Endoscopy revealed a flat elevated lesion about 15 mm in diameter adjacent to the duodenal papilla, the surface of which was uneven and covered with whitish granules. Based on the results of histological examination with immunohistochemistry (positive for CD10, CD20, CD79a, and bcl-2 protein, negative for CD5 and cyclin D1), a diagnosis of grade 1/3 follicular lymphoma was established. Systemic staging examinations suggested the lymphoma was restricted to the mucosa and superficial portion of the submucosa in the duodenal wall. The patient was treated with a combination of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and monoclonal anti-CD20 antibody (rituximab), in addition to radiotherapy. After six courses of this combination chemotherapy, complete regression of the lymphoma was observed. Although reports of small duodenal lymphoma (<20 mm or localized to the mucosa or submucosa) are extremely rare, the features of this case are characteristic of small duodenal lymphoma in terms of evolution around the ampulla of Vater, low-grade follicular type, occurrence in a women, occurrence in the fourth decade of life, and favorable outcome, and this type of tumor may need to be distinguished by pathogenesis and clinical behavior from various other gastrointestinal lymphomas. 相似文献
120.